Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bLAC for Cutaneous Warts in Kidney Transplant Patients
NCT00644579Phase 2Unknown
- Sponsor
- NatImmune
- Start
- Mar 2008
- Primary completion
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bLAC in cutaneous warts (3 arms), sponsored by NatImmune. Primary endpoint: Reduction in the area of wart lesions at 8 weeks. Status: unknown.
02
Drugs
bLAC
03
Conditions
cutaneous warts
Beyond the preview
Go deeper on NCT00644579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00644579.